Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss

Core Insights - Britain's regulator has approved an increase in the dosage of semaglutide to a maximum of 7.2 mg per week, up from the previous limit of 2.4 mg [1] Industry Impact - This approval may lead to expanded treatment options for patients, potentially increasing the market demand for semaglutide [1] - The change in dosage could enhance the drug's efficacy for weight management and diabetes treatment, influencing competitive dynamics within the pharmaceutical industry [1]